drugset / Trial / NCT00548860

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

NCT00548860

Phase 3 Completed 2018 enrolled American Regent, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.

Timeline

Start
2007-10
Primary completion
2009-03
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 15 mg/kg Intravenous

Indications